CJC-1295 & Ipamorelin: Complete Protocol Guide (UK 2026)

CJC-1295 combined with Ipamorelin is the most widely used peptide combination for enhancing growth hormone release in performance and longevity contexts. The stack works because CJC-1295 and Ipamorelin stimulate GH secretion through two entirely different receptor pathways — when combined, their GH-releasing effects are synergistic, producing pulses significantly larger than either compound alone. This guide covers the pharmacology, protocols, and practical considerations for UK users.

CJC-1295: The GHRH Analogue

CJC-1295 (also known as Mod GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that signals the pituitary to release GH. CJC-1295 binds the same receptor as GHRH (the growth hormone-releasing hormone receptor, or GHRH-R) but has been modified for improved stability and a longer half-life:

• Mod GRF 1-29 (CJC-1295 without DAC): Half-life approximately 30 minutes. Produces a physiological GH pulse that mimics natural pulsatile release. Most commonly used form for pulsatile protocols (injected at specific times to coincide with natural GH pulse windows).
• CJC-1295 with DAC (Drug Affinity Complex): Half-life extended to approximately 6–8 days through albumin binding via the DAC modification. Produces sustained elevation of GHRH receptor stimulation rather than pulsatile signalling. Results in more continuous but less physiological GH elevation. Typically injected once or twice weekly.

For most athletes, CJC-1295 without DAC (Mod GRF 1-29) combined with Ipamorelin is the preferred protocol — it produces the most physiological pattern of GH release with the most controllable pulsatile effect.

Ipamorelin: The Selective GHRP

Ipamorelin is a growth hormone-releasing peptide (GHRP) and ghrelin receptor agonist. It stimulates the ghrelin receptor on pituitary somatotrope cells, triggering GH release through a pathway entirely distinct from the GHRH receptor pathway activated by CJC-1295. Key properties:

• High GH selectivity: Ipamorelin is the most selective GHRP available — it stimulates GH release with minimal effect on cortisol, prolactin, or ACTH, which are increased (sometimes significantly) by the older GHRPs such as GHRP-2 and GHRP-6.
• Short half-life: Approximately 2 hours. Effects are transient and pulsatile — appropriate for timing with natural GH pulse windows.
• No significant appetite stimulation: Unlike GHRP-6 (which causes marked appetite increase through ghrelin pathway stimulation), Ipamorelin does not produce significant appetite stimulation. This makes it more practical for users who are not trying to increase caloric intake.

Why CJC-1295 + Ipamorelin Together?

The synergy is physiological. The hypothalamus releases GHRH to stimulate pituitary GH release, while ghrelin (the appetite/GH-regulating hormone) simultaneously activates the GHSR (ghrelin receptor) on the same pituitary cells. Both signals together produce a larger GH pulse than either alone. CJC-1295 + Ipamorelin mimics this dual-pathway stimulation:

• CJC-1295 activates the GHRH receptor (one pathway)
• Ipamorelin activates the ghrelin/GHSR receptor (complementary pathway)
• Together: synergistic GH pulse 2–10x larger than either peptide alone in animal and early human studies

Expected Benefits

• Increased GH and IGF-1: The primary pharmacological outcome; mediates most downstream effects
• Fat loss: GH-driven lipolysis; most pronounced in users with higher starting body fat and when injected in the fasted state
• Lean mass improvement: IGF-1-mediated protein synthesis enhancement; slower and more modest than anabolic steroids but meaningful over 3–6 months
• Improved sleep quality: Enhanced deep sleep (SWS) from pre-sleep injections; consistent user report and partially supported by GH's known role in SWS architecture
• Recovery enhancement: Collagen synthesis and connective tissue repair via IGF-1; complement to BPC-157/TB-500 protocols
• Skin quality: Improved skin thickness and elasticity from IGF-1-driven collagen and elastin synthesis

Dosing Protocol

Standard Protocol: Pre-Sleep Injection

• CJC-1295 (without DAC / Mod GRF 1-29): 100–300 mcg
• Ipamorelin: 100–300 mcg
• Timing: 30–60 minutes before sleep, on an empty stomach (no carbohydrates for 2 hours before injection)
• Frequency: Daily
• Rationale: The largest natural GH pulse occurs in the first 90 minutes of slow-wave sleep; combining exogenous GHRH + GHRP stimulation with this natural pulse maximises the GH burst

Multi-Injection Protocol (Fat Loss / Body Recomposition Priority)

• Injection 1: Morning, fasted — CJC-1295 100–200 mcg + Ipamorelin 100–200 mcg
• Injection 2: Pre-training (if training is >3 hours from last meal) — same doses
• Injection 3: Pre-sleep — same doses
• Total daily dose: 300–600 mcg of each peptide across 3 injections

CJC-1295 with DAC Protocol

• CJC-1295 with DAC: 1–2 mg twice weekly (Monday/Thursday)
• Ipamorelin: 100–300 mcg daily (at time of choosing — the once-weekly GHRH stimulation from DAC is combined with pulsatile GHRP for amplified effect)

Dosage Reference Table

Peptide	Standard Dose per Injection	Injections/Day	Minimum Protocol Duration
CJC-1295 w/o DAC	100–300 mcg	1–3	3–6 months
Ipamorelin	100–300 mcg	1–3	3–6 months
CJC-1295 with DAC	1–2 mg	2x per week only	3–6 months

Critical Timing Rule: The Carbohydrate Window

GH secretion is suppressed by elevated insulin. Eating carbohydrates within 2 hours of a peptide injection significantly blunts the GH pulse produced. This is the single most important practical protocol point: ensure a minimum 2-hour fast from carbohydrates before any CJC-1295 + Ipamorelin injection. Protein meals have less impact on insulin and are more permissive. For the pre-sleep injection: avoid carbohydrates after 8pm if injecting at 10pm; protein-only evening meals are acceptable.

Side Effects and Safety

• Water retention: Mild, particularly in the first 2–4 weeks. Self-limiting as the body adjusts.
• Tingling or numbness: Particularly in hands and feet; mild transient paraesthesia is common after injection and resolves within hours
• Mild fatigue: Some users note drowsiness after the pre-sleep injection — which is often desirable
• Insulin resistance: At higher doses, mild GH-driven insulin resistance may develop. Monitor fasting glucose if using 3x/day protocols for extended periods.
• No HPG axis effects: Testosterone, LH, FSH unaffected. No PCT required.
• No significant cortisol or prolactin elevation: Ipamorelin's selectivity avoids the cortisol/prolactin stimulation seen with GHRP-2 and GHRP-6.

For the broader HGH context and how these peptides compare to exogenous HGH, see our HGH complete guide and HGH dosage guide. Browse all peptide products.

Frequently Asked Questions

How long before CJC-1295 + Ipamorelin shows results?

Improved sleep quality is typically the first effect noticed — often within the first 1–2 weeks. Body composition changes (fat loss, lean mass improvement) become apparent from 6–12 weeks with consistent use and appropriate training and nutrition. Collagen and connective tissue benefits accumulate over 3–6 months.

Can you use CJC-1295 + Ipamorelin on a steroid cycle?

Yes — this is common and rational. The GH secretagogue effect synergises with anabolic steroid use through the mechanisms described in our HGH and peptide combination guide. No pharmacological interaction between the peptide stack and anabolic steroids is documented.

Ipamorelin vs GHRP-6: Which is better?

For most athletes, Ipamorelin is preferable. It produces equivalent or superior GH release with dramatically less cortisol and prolactin stimulation, and without the significant appetite increase associated with GHRP-6. GHRP-6's appetite effect can be useful during a bulk phase when increasing caloric intake is a goal, but counterproductive during a cut or recomposition.